Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient has given written informed consent before any trial-related activity is performed
Has a confirmed prostate cancer in which this type of treatment is needed.
You may not be if
Previous treatment for prostate cancer
Previous trans-urethral resection of the prostate
Current use of 5-alpha reductase inhibitor or α-adrenoceptor antagonist.
Patients in need of external beam radiotherapy to be started at the same time as hormone therapy
Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)
History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
Hypersensitivity towards any component of the investigational product
Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.
Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.
Clareo Health | Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
